Intraperitoneal Mitoxantrone vs. Intraperitoneal FUdR for Ovarian Cancer Patients with Minimal Residual Disease after Second-Look Surgery, A Randomized Phase II Pilot

Phase II selection designs

PY Liu Handbook of Statistics in Clinical Oncology :119-127

Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy

G Samimi;D Fink;NM Varki;A Husain;WJ Hoskins;DS Alberts;SB Howell Clinical Cancer Research 6:1415-1421

False positive rates of randomized phase II designs

PY Liu;M LeBlanc;M Desai Controlled Clinical Trials 20:343-352

Intraperitoneal mitoxantrone or floxuridine: Effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy-A randomized phase II study by the Southwest Oncology Group.

FM Muggia;PY Liu;DS Alberts;DL Wallace;RV O'Toole;KY Terada;EW Franklin;GW Harrer;DA Goldberg;EV Hannigan Gynecologic Oncology 61:395-402

Elevated serum CA-125: An adverse prognostic factor for survival in epithelial ovarian cancer (EOC) with minimal residual disease after second-look laparotomy (SLL)

F Muggia;PY Liu;DS Alberts;K Terada;RJ Belt;HJ Schmidt;TW Pollock;EB Weiser;DW Blayney;D Wallace;R O'Toole ASCO 14:270(#750)

Intraperitoneal (IP) mitoxantrone vs. intraperitoneal floxuridine in ovarian cancer patients with minimal residual disease after second-look surgery, a randomized phase II pilot.

F Muggia;D Alberts;P Liu;K Terada;D Wallace ASCO 13:249(#782)

CA-125: A predictor of outcome from intraperitoneal (IP) therapy in Southwest Oncology Group study 8835.

C Truesdal;FM Muggia;DS Alberts;PY Liu;J O'Sullivan;D Wallace ASCO 10:195(#644)